

VIVANZA BIOSCIENCES LIMITED

Regd. Office: 403, Sarthik 2, Opp. Rajpath Club, S. G. Highway, Ahmedabad 380054.

Phone: 07405699869, email: info@vivanzabiosciences.com, website: www.vivanzabiosciences.com

CIN: L24110GJ1982PLC005057

February 10, 2022

To,
Department of Corporate Services
BSE Limited
25th Floor, P. J. Tower,
Dalal Street,
Fort, Mumbai- 400 001

Dear Sir/Madam,


Sub: Outcome of Board Meeting.

This is to inform you that the Board of Directors of the Company in its meeting held today i.e. on Thursday, February 10, 2022 from 5:00 p.m. to 6:45 p.m., at the Registered Office of the Company, inter alia has Considered and approved the Standalone and Consolidated Unaudited Financial Results of the Company for the Quarter and nine months ended December 31, 2021 along with Limited Review Report thereon as per Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Please take the same on your records.

Thanking You,

Yours Sincerely,
For, Vivanza Biosciences Limited


Jainil Bhatt
Chief Financial Officer*



Encl:

1. Unaudited Standalone and Consolidated Financial Results for the Quarter ended December 31, 2021.
2. Limited Review Report on Standalone and Consolidated Financial Results.

VIVANZA BIOSCIENCES LIMITED

Regd. Office: 403, Sarthik 2, Opp. Rajpath Club, S. G. Highway, Ahmedabad 380054.

CIN : L24110GJ1982PLC005057

Tel No.: 079-26870852/54 Email: info@vivanzabiosciences.com Website: www.vivanzabioscience.com

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED DECEMBER 31, 2021.

(Rs. in Lacs except per share data)

Particulars	Quarter Ended			Nine Month Ended		Year Ended
	31/12/2021	30/09/2021	31/12/2020	31/12/2021	31/12/2020	31/03/2021
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1 Income from Operations						
(a) Revenue from operations	152.04	183.28	350.41	355.08	642.74	922.34
(b) Other income	2.19	2.84	3.77	53.36	39.70	49.98
Total Income	154.23	186.12	354.18	408.44	682.44	972.32
2 Expenses						
(a) Cost of Materials consumed	0.00	0.00	0.00	0.00	0.00	0.00
(b) Purchase of stock-in-trade	447.17	175.77	201.93	634.16	551.95	810.62
(c) Increase/Decrease in inventories of FG, WIP and stock-in-trade	-317.63	-0.48	146.31	-319.69	33.29	45.86
(d) Employee benefits expense	2.09	0.82	6.47	4.56	25.02	29.08
(e) Finance Cost	9.93	9.50	11.35	30.88	36.37	46.76
(f) Depreciation and amortisation expense	0.00	0.18	0.34	0.36	0.83	0.98
(g) Other expenses	12.61	2.09	2.38	22.89	13.58	24.42
Total Expenses	153.97	187.88	368.78	373.26	660.84	857.52
3 Profit(loss) before exceptional items and tax (1-2)	0.26	-1.76	15.40	35.18	21.60	14.79
4 Exceptional Items	0.00	-28.70	0.00	-28.70	0.00	0.00
5 Profit(Loss) before tax (3-4)	0.26	26.94	15.40	63.88	21.60	14.79
6 Tax Expense						
(a) Current tax	0.00	0.00	0.00	0.00	0.00	4.85
(b) Deferred tax	0.00	0.00	0.00	0.00	0.00	-0.04
Total Tax Expenses	0.00	0.00	0.00	0.00	0.00	4.82
7 Profit / (Loss) for the period from continuing operations (5-6)	0.26	26.94	15.40	63.88	21.60	9.98
8 Profit (Loss) from discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00
9 Tax Expense of discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00
10 Profit (Loss) from discontinuing operations (after tax)	0.00	0.00	0.00	0.00	0.00	0.00
11 Other Comprehensive Income						
A(i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
B (i) Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
Other Comprehensive Income for the period	0.00	0.00	0.00	0.00	0.00	0.00
12 Total Comprehensive Income for the period	0.26	26.94	15.40	63.88	21.60	9.98
13 Paid-up equity share capital (Face value of Rs. 10/- each)	400	400	400	400	400	400
14 Other Equity	-	-	-	-	-	-63.49
15 Earnings Per Share (before extraordinary items) (not annualised):						
(a) Basic	0.01	0.67	0.39	1.60	0.54	0.25
(b) Diluted	0.01	0.67	0.39	1.50	0.54	0.25
16 Earnings Per Share (after extraordinary items) (not annualised):						
(a) Basic	0.01	0.67	0.39	1.50	0.54	0.25
(b) Diluted	0.01	0.67	0.39	1.50	0.54	0.25

Notes:

1. The above standalone financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on February 10, 2022. The Limited Review under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 has been carried out by the statutory auditors. The Limited Review Report does not contain any observation which could have an impact on the results for the quarter ended December 31, 2021.

2. The Company adopted the Indian Accounting Standards ('Ind AS') effective 1st April, 2017 (transition date 1st April, 2016). The financial results have been prepared in accordance with Ind AS as prescribed under Section 133 of the Companies Act, 2013 read with the relevant Rules issued there under.

3. The Company operates only in single segment i.e pharmaceuticals related activities.

Date : 10/02/2022
Place : Ahmedabad



For VIVANZA BIOSCIENCES LIMITED

JAINI BHATT

CFO

PAN: AJDPB2629L



UDIN: 22163940ABEDQM6656

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To

The Board of Directors,
Vivanza Biosciences Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Vivanza Biosciences Limited for the quarter ended 31 December 2021 ("the Statement") attached herewith being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" - ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review'

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of interim Financial information Performed by the independent Auditor of the Entity," issued by the institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.



For, G M C A & CO.
Chartered Accountants
FRN: 109850W

CA. Mitt S. Patel
Partner

Membership No: 163940

Place: Ahmedabad

Date: 10th February, 2022

VIVANZA BIOSCIENCES LIMITED

Regd. Office: 403, Sarthik 2, Opp. Rajpath Club, S. G. Highway, Ahmedabad 380054

CIN : L24110GJ1982PLC005057

Tel No.: 079-26870952/54 Email: info@vivanzabiosciences.com Website: www.vivanzabiosciences.com

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED DECEMBER 31, 2021.

(Rs. in Lacs except per share data)

Particulars	Quarter Ended			Nine Month Ended		Year Ended
	31/12/2021	30/09/2021	31/12/2020	31/12/2021	31/12/2020	31/03/2021
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1 Income from Operations						
(a) Revenue from operations	152.04	280.82	407.98	455.49	349.50	988.83
(b) Other Income	2.19	2.90	4.08	53.42	31.94	50.56
Total Income	154.22	283.72	412.06	508.90	381.44	1039.39
2 Expenses						
(a) Cost of Materials consumed	0.00	0.00	0.00	0.00	0.00	0.00
(b) Purchase of stock-in-trade	448.05	263.08	243.46	722.36	379.72	883.92
(c) Increase/Decrease in inventories of FG, WIP and stock-in-trade	-318.71	2.70	129.78	-315.41	-48.12	31.38
(d) Employee benefits expense	6.54	7.37	7.54	19.98	18.45	33.91
(e) Finance Cost	9.93	9.50	11.35	30.98	10.19	46.76
(f) Depreciation and amortisation expense	0.00	0.18	0.34	0.36	0.18	0.98
(g) Other expenses	13.17	3.71	3.02	26.03	12.02	30.09
Total Expenses	158.98	286.54	395.48	484.30	372.44	1027.04
3 Profit/(loss) before exceptional items and tax (1-2)	-4.76	-2.82	16.57	24.60	9.00	12.35
4 Exceptional Items	0.00	-28.70	0.00	-28.70	0.00	0.00
5 Profit/(Loss) before tax (3-4)	-4.76	25.88	16.57	63.30	9.00	12.35
6 Tax Expense						
(a) Current tax	0.00	0.00	0.00	0.00	0.00	4.85
(b) Deferred tax	0.00	0.00	0.00	0.00	0.00	-0.04
Total Tax Expenses	0.00	0.00	0.00	0.00	0.00	4.81
7 Profit / (Loss) for the period from continuing operations (5-6)	-4.76	25.88	16.57	63.30	9.00	7.54
8 Profit (Loss) from discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00
9 Tax Expense of discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00
10 Profit (Loss) from discontinuing operations (after	0.00	0.00	0.00	0.00	0.00	0.00
11 Other Comprehensive Income						
A(i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
B (i) Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
Other Comprehensive income for the period	0.00	0.00	0.00	0.00	0.00	0.00
12 Total Comprehensive Income for the period	-4.76	25.88	16.57	63.30	9.00	7.54
13 Paid-up equity share capital (Face value of Rs. 10/- each)	400	400	400	400	400	400
14 Other Equity	-	-	-	-	-	-84.06
15 Earnings Per Share (before extraordinary items) (not annualised):						
(a) Basic	-0.12	0.65	0.41	1.33	0.23	0.19
(b) Diluted	-0.12	0.65	0.41	1.33	0.23	0.19
16 Earnings Per Share (after extraordinary items) (not annualised):						
(a) Basic	-0.12	0.65	0.41	1.33	0.23	0.19
(b) Diluted	-0.12	0.65	0.41	1.33	0.23	0.19

Notes:

1. The above standalone financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on February 10, 2022. The Limited Review under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 has been carried out by the statutory auditors. The Limited Review Report does not contain any observation which could have an impact on the results for the quarter ended December 31, 2021.

2. The Company adopted the Indian Accounting Standards ('Ind AS') effective 1st April, 2017 (transition date 1st April, 2016). The financial results have been prepared in accordance with Ind AS as prescribed under Section 133 of the Companies Act, 2013 read with the relevant Rules issued there under.

3. The Company operates only in single segment i.e. pharmaceuticals related activities.

For, VIVANZA BIOSCIENCES LIMITED




JAINL BHATT
 CEO
 PAN: AADPB2629L

Date : 10/02/2022
Place : Ahmedabad



GMCA & Co.

Chartered Accountants

UDIN: 22163940ABEHB07882

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To
The Board of Directors,
Vivanza Biosciences Limited

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Vivanza Biosciences Limited which includes joint operations (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), for the quarter ended December 31, 2021 and year to date from April 01, 2021 to December 31, 2021 ("the Statement") attached herewith. being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors. has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34) "Interim Financial Reporting prescribed under Section 133 of the Companies Act 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the SEBI Circular CIR/CFD/CMD1/44/2019 dated 29 March 2019 issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), to the extent applicable.






4. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, the SEBI Circular and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. The Statement includes the interim financial information of Vivanza LifeSciences Pvt Ltd. (Subsidiaries), which have been reviewed / audited by their auditors, and have been furnished to us by the Holding Company's management. Our Conclusion on the Statement, and our report in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), read with SEBI Circular, in so far as it relates to the aforesaid joint venture s are based solely on such audited / reviewed interim financial information.
6. Our conclusion is not modified in respect of this matter.



For, G M C A & CO.
Chartered Accountants
FRN: 109850W


CA. Mitt S. Patel
Partner
Membership No: 163940

Place: Ahmedabad
Date: 10th February, 2022